Oncologists in their own words on AI in clinical practice — knowledge tools, patient-facing AI, AI-derived biomarkers, and regulation. Every post verbatim and in full.
The Oncology Brothers (Drs. Rahul and Rohit Gosain) announced the OpenEvidence partnership on X this week. Asked how it works, they replied that OpenEvidence “will supplement published data with our panelists quotes from the podcast.” The screenshots show the format: a “Verbatim Expert Perspective” card credited “Originally shared on Oncology Brothers.” On Nov 13, Katy Beckermann posted a slide showing the same format for The Uromigos. As of Nov 19 we found no press release or announced terms from OpenEvidence, the Oncology Brothers or The Uromigos.
In this edition: Roupen Odabashian, MD on the randomized trial where AI-triggered trial notifications did not change enrollment — and on launching an AI agent that tracks approvals · Benjamin Herzberg, MD on the slowest step in AI drug development · Jason Locasale on Astra drafting five NIH R01 proposals in about an hour · Jame Abraham, MD on OpenEvidence's new model family · Katy Beckermann, MD on chart-finding time · the Oncology Brothers on bias, privacy, and liability · Arturo Loaiza-Bonilla, MD on verifying AI alignment · Hidehito Horinouchi, MD on the IASLC AI Taskforce surveys · NEJM AI on agentic research workflows · Plus the thread: Masahiro Torasawa, MD, PhD on the WCLC26 abstract database he built with Astra, and Guilherme Correia, MD's response.
In this edition: Eric Topol, MD on AI detecting pancreatic cancer up to 3 years before diagnosis · Yan Leyfman, MD on the governance gap — 83% of surveyed oncology clinicians use AI independently, 71% report no institutional policy · Katy Beckermann, MD on Epic running Anthropic's Mythos across its own codebase · Chadi Nabhan, MD on AI tumor twins with Bishoy Faltas, MD.
In this edition: Mali Barbi, MD asks whether AI-read TILs are the next PD-L1 · Ilana Schlam, MD shares AI TIL data from NSABP B-41 · Samer Al Hadidi, MD publishes 'Peer-Unreviewed' in Annals of Internal Medicine and Eric Topol, MD flags it · Karun Neupane, MD on omission errors in AI summaries · Sawyer Bawek, DO on Doximity's 66% physician AI adoption · Laura Heacock, MD on residents outperforming radiology AI · Allan Pereira, MD, PhD on the LiON prospective AI reader in Nature Medicine · Hidehito Horinouchi, MD and Fabio Moraes, MD preview AI at WCLC26 · Zeke Emanuel, MD on AI's improvement curve · Anish Koka, MD debates the Khosla thesis · Andrew Portuguese, MD builds with local AI · Arturo Loaiza-Bonilla, MD on Amara's law and the AI Oncology Revolution podcast · Shiv Rao, MD on Abridge's thesis · Yair Einhorn on AI's limits in biotech R&D · Bo Wang on the AI-designed individualized vaccine trial · VJHemOnc on an ML six-gene myeloma signature
In this edition: JAMA's new Perspective argues AI alone may exceed physicians on cognitive medical tasks · co-authors Zeke Emanuel, MD and Vinod Khosla make the case · Eric Topol, MD flags the argument · Yakup Ergün, MD largely agrees — and says what physicians still own · physician-founder Joseph Younis, MD on the paper's conflicts of interest · Santhosh Ambika, MD on workforce oversupply · Jeff Ryckman, MD on Abridge saving an hour a day — and on an EviCore denial built on AI-hallucinated literature · Jean-Charles Soria, MD on AI in pharma R&D · The ASCO Post's AI week in review.
In this edition: Aaron Goodman, MD on AI replacing UpToDate · David S. Hong, MD on building his own RAS dashboard · Noah Lindenberg, MD on the limits of OpenEvidence · Yüksel Ürün, MD on where JAMA draws the line between AI assistance and authorship · Hashem El-Serag, MD on JAMA's new manuscript guidance · The ASCO Post on a study in which physicians kept following incorrect AI classifications.
In this edition: Aaron Goodman, MD on AI replacing UpToDate in daily use · Katy Beckermann, MD, PhD on AI tools in the community clinic · Estela Rodriguez, MD on patients bringing AI answers to the visit · Antonio Giordano, MD, PhD on AI-scored TROP2 · Andrew Pannu on AI in biopharma intelligence teams · Jame Abraham, MD on Cleveland Clinic's AI Summit, Aug 28.
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement: